ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,083.57
      0.36%
      US Tech 100
      21,162.80
      0.42%
      Dow Jones
      44,747.63
      -0.28%
      Brent Oil
      74.385
      0.30%
      Bitcoin
      97,416.16
      0.87%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Canada
      5. TSXV

      6. Acasti Pharma Inc (ACST) Quote

      Acasti Pharma Inc

      Acasti Pharma Inc (ACST)

      Acasti Pharma Inc
      0.58
      0.00
      (0.00%)
      Closed February 06 4:00PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      0.58
      Bid
      0.58
      Ask
      0.98
      Volume
      -
      0.00 Day's Range 0.00
      0.58 52 Week Range 0.58
      Market Cap
      5.451M
      Previous Close
      0.58
      Open
      -
      Last Trade
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      -
      Shares Outstanding
      9,399,000
      Dividend Yield
      -
      PE Ratio
      -2.46
      Earnings Per Share (EPS)
      -1.37
      Revenue
      -
      Net Profit
      -12.85M

      About Acasti Pharma Inc

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.acastipharma.com
      Headquarters
      Jersey City, New Jersey, USA
      Founded
      -
      Acasti Pharma Inc is listed in the Pharmaceutical Preparations sector of the TSX Venture Exchange with ticker ACST. The last closing price for Acasti Pharma was $0.58. Over the last year, Acasti Pharma shares have traded in a share price range of $ 0.58 to $ 0.58.

      Acasti Pharma currently has 9,399,000 shares outstanding. The market capitalization of Acasti Pharma is $5.45 million. Acasti Pharma has a price to earnings ratio (PE ratio) of -2.46.

      Ask ADVFN Intelligence (AI)

      ACST Latest News

      More News

      Acasti Pharma Reports Third Quarter 2023 Operational Results

      Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a...

      February 14 2023
      GlobeNewswire Inc.

      Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

      LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

      January 25 2023
      GlobeNewswire Inc.

      Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

      LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

      January 24 2023
      GlobeNewswire Inc.

      Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

      LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

      January 13 2023
      GlobeNewswire Inc.

      Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

      LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

      January 05 2023
      GlobeNewswire Inc.

      Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

      LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

      December 28 2022
      GlobeNewswire Inc.

      Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

      LAVAL, Québec, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

      December 22 2022
      GlobeNewswire Inc.

      Acasti Pharma Reports Second Quarter 2023 Operational Results

      Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a...

      November 14 2022
      GlobeNewswire Inc.

      Acasti Pharma to Present at Q4 Investor Summit

      LAVAL, Québec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three...

      November 09 2022
      GlobeNewswire Inc.

      Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

      LAVAL, Quebec, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical...

      November 07 2022
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1000.580.580.5800CS
      4000.580.580.5800CS
      12000.580.580.5800CS
      26000.580.580.5800CS
      52000.580.580.5800CS
      156-0.91-61.07382550341.491.660.4713461.01414825CS
      260-0.41-41.41414141410.993.680.22934290.76617726CS

      ACST - Frequently Asked Questions (FAQ)

      What is the current Acasti Pharma share price?
      The current share price of Acasti Pharma is $ 0.58
      How many Acasti Pharma shares are in issue?
      Acasti Pharma has 9,399,000 shares in issue
      What is the market cap of Acasti Pharma?
      The market capitalisation of Acasti Pharma is CAD 5.45M
      What is the 1 year trading range for Acasti Pharma share price?
      Acasti Pharma has traded in the range of $ 0.58 to $ 0.58 during the past year
      What is the PE ratio of Acasti Pharma?
      The price to earnings ratio of Acasti Pharma is -2.46
      What is the reporting currency for Acasti Pharma?
      Acasti Pharma reports financial results in USD
      What is the latest annual profit for Acasti Pharma?
      The latest annual profit of Acasti Pharma is USD -12.85M
      What is the registered address of Acasti Pharma?
      The registered address for Acasti Pharma is 103 CARNEGIE CENTER, SUITE 300 PRINCETON, JERSEY CITY, NEW JERSEY, 08540
      What is the Acasti Pharma website address?
      The website address for Acasti Pharma is www.acastipharma.com
      Which industry sector does Acasti Pharma operate in?
      Acasti Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      SMAR.PSmartset Services Inc
      $ 0.075
      (150.00%)
      		13k
      CNST.PConstellation Capital Corp
      $ 0.07
      (75.00%)
      		1,000
      GLIGlacier Lake Resources Inc
      $ 0.07
      (75.00%)
      		1,000
      DGTL.HDGTL Holdings Inc
      $ 0.045
      (50.00%)
      		46.02k
      MKRMelkior Resources Inc
      $ 0.105
      (50.00%)
      		203.5k
      GHR.HGolden Harp Resources Inc
      $ 0.04
      (-57.89%)
      		1.3k
      MTKMontauk Metals Inc
      $ 0.005
      (-50.00%)
      		22k
      SAI.HSunshine Agri Tech Inc
      $ 0.005
      (-50.00%)
      		1,000
      BECNBeacn Wizardry & Magic Inc
      $ 0.04
      (-50.00%)
      		6k
      MMNMonarca Minerals Inc
      $ 0.005
      (-50.00%)
      		118.4k
      DMDataMetrex AI Limited
      $ 0.005
      (0.00%)
      		8.61M
      RSLVReyna Silver Corp
      $ 0.07
      (0.00%)
      		3.05M
      LIOLion One Metals Limited
      $ 0.30
      (-22.08%)
      		3.03M
      OMGOmai Gold Mines Corp
      $ 0.43
      (-6.52%)
      		2.47M
      NDANeptune Digital Assets Corp
      $ 1.94
      (-5.83%)
      		2.37M

      Discussion

      View Full Feed
      Trum Trum 3 minutes ago
      LOL... you one of the dumpers here? you really don't like it when an investor can cover their original investment and make several K more? has seems like we know who some of the insider dumpers are now
      RITE
      janice shell janice shell 3 minutes ago
      LOLOLOL!!
      CanItBThisEZ2Make CanItBThisEZ2Make 4 minutes ago
      $MAXN
      Buy: 136,075
      Neutral: 60,715
      Sell: 210,607
      Volume: 407,397
      MAXN
      Steady_T Steady_T 4 minutes ago
      I think you are missing a few details. The artisanal production method was inspected and approved for human consumption which I believe allowed for the compassionate use. I haven't checked into it, but artisanal may have had to be inspected prior to trial use. Someone on the board will know the answ
      NWBO
      TenKay TenKay 4 minutes ago
      Well we learned a few things today…one being that the big sellers can count on the “Humbl” brand confusion to dump stock for another 60 days.

      But I am getting more interested in what is going on with the fertilizer. That seemed to be SMX’s concern…and now apparently HUMBL’s as well…a
      SMX
      Dj2490 Dj2490 5 minutes ago
      I also will load up quickly here if price keeps dropping.
      GDVM
      unlimitedgains4 unlimitedgains4 5 minutes ago
      What are your thoughts on this?? Sounds like a good idea to me ! https://www.reddit.com/r/HMBLblockchain/comments/1iji1wq/humbls_recent_restructuring_and_strateg
      HMBL
      janice shell janice shell 6 minutes ago
      LOL!! They don't lay eggs in water.

      https://investorshub.advfn.com/uimage/uploads/2025/2/6/yvnbdimage.jpeg

      https://wildlifecenter.org/help-advice/managing-wildlife-conflicts-and-habitats/mallard-duck-nests
      Amigo Mike Amigo Mike 7 minutes ago
      ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
      February 06, 2025 04:36 PM Eastern Standard Time

      TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing t
      ZIVO
      Involuntary-Recluse Involuntary-Recluse 7 minutes ago
      Some do, most don't because of the PL designation.
      If Ben files the MC, then PC is reestablished and all brokers allow buys.

      The spread will remain wide for several reasons IMHO,

      Many shares are held by tight hands betting on a big payday,
      FOMO is at play,
      CLHI
      littlejohn littlejohn 8 minutes ago
      7% weekly growth in production of Natural Gas

      Plant Liquids for week ending 01/31/2025...

      9% weekly increase versus year ago...

      https://ir.eia.gov/wpsr/overview.pdf

      Plenty of fuel to keep folks warm...

      LNG exports flat agains
      janice shell janice shell 8 minutes ago
      Ahhh, what a lovely couple they are. Time for the Missus to go off to Assisted Care. Her somewhat younger paramour is more than free to return to South Africa.
      Patrick Bateman Patrick Bateman 9 minutes ago
      And this will end up being way larger than announced...

      https://x.com/bhwizzy/status/1887669421981786514?s=46&t=UPrlL6UHP6PoDS3E0Tkksw
      RITE
      havnagoodtime havnagoodtime 9 minutes ago
      I'm sure the amendment will be explained to you so you'll be able to understand, with the usual clarity >>

      I believe what they meant was ... I expect to see that they will ... I feel they are going to ... It is likely that what will happen is ... ... ... ...
      HMBL
      TenKay TenKay 9 minutes ago
      Since the 8K said “acquired” let’s assume that HMBL “owns” the $20 million worth of fertilizer?

      The real question is why would they need to check on its value now? Did they not do that prior to the acquisition?

      Are they going to write down a bunch of it out of the gate
      HMBL
      thecrusher2011 thecrusher2011 9 minutes ago
      Are you ready for your head to explode?

      2 days ago.....long after all this happened.....
      https://www.newsweek.com/donald-trump-approval-rating-popularity-polls-2025738

      I bet when women find out that he saved sports for them and kept the men out it will go up eve
      crowin crowin 9 minutes ago
      Let's have this conversation in about. 2 years from now if Trump was good or not!
      djjazzyjeff djjazzyjeff 9 minutes ago
      That must be lerloonimab!!!!!!!11111!@1
      CYDY
      Jetmek_03052 Jetmek_03052 9 minutes ago
      Wonderful.

      So don’t make some sort of statement about “blue chips are down bad this week” and expect it to somehow correlate to DBMM.

      Say “the blue chips I have in MY PORTFOLIO are down this week”.

      But whatever. There is STILL ZERO CORRELATION between
      DBMM
      Amigo Mike Amigo Mike 9 minutes ago
      In the category of ..... I JUST DON'T GET IT .... ZIVO releases news starting a new study with the University of Delaware ...... AFTER F*^&ING HOURS ........ I dunno for what purpose.

      https://www.businesswire.com/news/home/20250206639313/en/ZIVO-Bioscience-Plans-New-Study-with-Univer
      ZIVO
      B402 B402 9 minutes ago
      Enough for now mike, we agree on the most important

      Lets see if dems will fight everything......Or make sure about the constitution....... One thing they don't get, and need to, is its time...........

      And speaking of that, its my time.........Good day
      carlson carlson 9 minutes ago
      POG 2886 USD 3000 NEXT!!!
      NBRI

      Your Recent History

      TSXV
      ACST
      Acasti Pharma
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads